|
 |
Advertisement:
When Questionable Water Quality is Never an Option
Shimadzu’s TOC-VW Wet Chemical Analyzer utilizes the exclusive Heated-UV-Persulfate oxidation method to provide rapid, efficient breakdown of hard-to-oxidize compounds, ensuring ultra-pure water for pharmaceutical applications. Reduce analysis time with such features as random-access autosampler control and a high-sensitivity NDIR detector that eliminates false peaks. In addition, low-cost consumables significantly reduce the cost of ownership.
 Learn More.
|
|
Abbott (Abbott Park, IL) acquired the global rights to PanGenetics’s (Royston, UK) PG110 fully humanized antibody to nerve growth factor (NGF). The agreement includes an upfront payment of $170 million plus additional milestone payments, for a total of up to $190 million. PG110 is a biologic currently being studied in a Phase I clinical trial in patients with osteoarthritis. If the Phase I trial is successful, Abbott anticipates evaluating the compound in a number of other pain states, including chronic lower back pain, cancer pain and diabetic neuropathic pain, according to a company press release.
Almac (Craigavon, UK) recently launched site-specific PEGylation technology services. The technology focuses on the engineering of both recombinant proteins and synthetic peptides.
Bristol-Myers Squibb (BMS, New York) will split off its holdings in Mead Johnson Nutrition Company. The company expects the split-off to be a tax-advantaged way to deliver value to Bristol-Myers Squibb shareholders, according to a company press release.
In a separate announcement, BMS said it formed an agreement with Alder Biopharmaceuticals (Bothell, WA) to develop and commercialize ALD518, a biologic that has completed Phase IIa development for the treatment of rheumatoid arthritis. BMS gains worldwide exclusive rights to develop and commercialize ALD518 for all potential indications except cancer, for which Alder will retain rights and grant Bristol-Myers Squibb an option to co-develop and commercialize outside the United States. Alder will receive an upfront cash payment of $85 million, potential development and regulatory milestone payments of up to $764 million, potential sales-based milestones of more than $200 million, and royalties on net sales.
Advertisement:
Training Will Get You Up to Speed and Get Ahead
Do you …Want to be more effective and competitive in today’s changing world? Want access and understanding of the latest regulations/new technologies? Want to learn from leading industry experts? CfPA’s Accredited Training offers you public and online courses to ensure you receive the skills and knowledge that will make a difference in your career. Learn more at  www.cfpa.com
|
GlaxoSmithKline Biologicals (GSK, London) and Nabi Biopharmaceuticals (Rockville, MD) formed an option and licensing agreement for a nicotine conjugate candidate vaccine, NicVAX, an investigational vaccine for the treatment of nicotine addiction and the prevention of smoking relapse, as well as for the development of a second-generation nicotine vaccine. Under the agreement, GSK will pay Nabi $40 million upfront and more than $500 million in option fees and milestone payments. Nabi will also receive double-digit royalties on global sales of NicVAX, should GSK exercise its option, as well as royalties on global sales of next generation nicotine vaccines.
Genzyme (Cambridge, MA) issued letters to healthcare providers regarding its enzyme replacement products Cerezyme (imiglucerase for injection), Fabrazyme (agalsidase beta), Myozyme (alglucosidase alfa), Aldurazyme (laronidase), as well as Thyrogen (thyrotropin alfa for injection), filled at its Allston Landing manufacturing facility. The letters remind providers of the product labeling recommendations advising both visual inspection of vials and in-line filtration of the products to look for foreign particles. Genzyme’s quality control processes have detected foreign particles in these products at a rate of approximately 1%, according to a press release, which also stated that the company’s rate has not increased over time.
Advertisement:
Surety Protects ELN Content Integrity, Ensures Authenticity
As a pharmaceutical or biotechnology organization, your formulas, treatments and discoveries are the “lifeblood” of your business. But if you aren't protecting the integrity of your scientific content, you risk losing ownership, revenue and consequently your business if you can't prove time-of-creation and authenticity. Learn how you can implement simple, cost-effective, and transparent controls to protect your intellectual property data –
 get the free whitepaper now
|
In a separate announcement, Genzyme said it received a complete response letter from FDA regarding its application to market Lumizyme (alglucosidase alfa) for the treatment of Pompe disease. The agency stated that satisfactory resolution of deficiencies related to the Allston Landing manufacturing plant are required before the Lumizyme application can be approved. Genzyme believes the other elements of the Lumizyme review, such as the risk evaluation and mitigation strategy (REMS), the product label, and post-marketing requirements, have been satisfactorily addressed. Genzyme said it would transition production of alglucosidase alfa 2000-L scale (Lumizyme) to its facility in Geel, Belgium, and is working with FDA to complete the necessary approvals.
Onyx Pharmaceuticals (Emeryville, CA) acquired Proteolix (South San Francisco, CA), a biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. N. Anthony Coles, president and chief executive officer of Onyx, said in a company press release, “The lead asset, carfilzomib, with its potential for an accelerated approval in 2011, may provide the next generation of therapy for patients with multiple myeloma who often relapse or become resistant to current treatment options.”
Advertisement:
Lancaster Laboratories Will Solve Your Raw Materials Testing Challenges
When raw materials challenges require timely, innovative solutions, Lancaster Laboratories is the trusted source to deliver desired results. With unmatched scientific expertise, capabilities and service, Lancaster Laboratories offers comprehensive raw materials testing, including USP and EP harmonization. Expect quality, 24/7 availability, specialization and on-time delivery. Customized services available. Discover why customers rank Lancaster Laboratories their #1 Lab of Choice consecutively since 1996.
 Click here for your Raw Materials solutions |
The contract research organization Particle Sciences (Bethlehem, PA) acquired additional space, bringing its total to approximately 21,000 ft2. The company plans to use the space for a purpose-built sampling and weighing area for highly potent materials and for clinical trial material manufacturing, according to a press release. Particle Sciences expects the new space to be operational in early 2010.
sanofi aventis (Paris) and Regeneron Pharmaceuticals (Tarrytown, NY) extended their existing global collaboration to discover, develop, and commercialize fully-human therapeutic monoclonal antibodies. sanofi aventis will increase its annual funding commitment from $100M to $160 million beginning in 2010, and the research funding will now extend through 2017. The companies aim to advance an average of four to five antibodies into clinical development each year, and sanofi aventis has an option to extend the discovery program for up to an additional three years for further antibody development and preclinical activities, according to a company press release.
Advertisement:
Up to 95% solvent savings with ACQUITY UPLC
If you're interested in solvent savings and productivity gains, the Waters ACQUITY UPLC® System has been proven to have the lowest demand for solvent use - up to 95% less - in addition to significant productivity and analytical quality gains. There's never been a better time to switch to ACQUITY UPLC.
 Calculate your savings now. |
Sciele Pharma (Atlanta, GA), a Shionogi & Co. (Osaka, Japan) company, will acquire Addrenex Pharmaceuticals (Durham, NC), a pharmaceutical company specializing in drugs that regulate the adrenergic system, for $29 million in cash. Sciele previously licensed three products from Addrenex: Clonicel (clonidine HCl sustained release) for attention deficit hyperactivity disorder, Jenloga XR (once-daily clonidine) for hypertension, and rights to ADX-415 for the treatment of vasomotor systems and hypertension. The new drug application for Clonicel was filed with the US Food and Drug Administration in October 2009.
Do you have news to report on facility expansions, contracts, service agreements, mergers, acquisitions, or personnel appointments? Send press releases to ptpress@advanstar.com
|
|
The US Food and Drug Administration announced on Nov. 12, 2009, that it approved the use of the CSL’s (Melbourne, Australia) seasonal and influenza A (H1N1) vaccines to include children ages 6 months and older. These vaccines were previously approved for use in adults ages 18 years and older. “Because children are among those most vulnerable to the 2009 H1N1 virus, having a broader range of vaccines available for use in children is an important step in responding to the H1N1 outbreak,” Margaret A. Hamburg, commissioner of FDA, said in a press release. The vaccines will be available both in single-dose, preservative-free, prefilled syringes and in multidose vials that contain thimerosal, a mercury derivative, as a preservative.
In related news, FDA approved a fifth vaccine for protection against the influenza A (H1N1) virus. Manufactured by ID Biomedical (Quebec), which is owned by GlaxoSmithKline, the vaccine uses the “established, licensed egg-based manufacturing process used for producing seasonal flu vaccine,” according to an FDA release. ID Biomedical’s monovalent vaccine will be produced in multi-dose vials, in a formulation that contains thimerosal.
|
Advertisement:
Enwave Optronics, Inc. is the innovative leader in affordable Raman spectroscopy solutions. Enwave offer portable Raman instruments with best performances and prices in the industry. Raman microscopes and high sensitivity Raman instruments with the best performance-to-price ratios are also available.
 Click here to read more.
|
|
Cannasat Therapeutics (Toronto) appointed Anthony J. Giovinazzo president and CEO. Giovinazzo succeeds David Hill as CEO, and Hill will continue with the company as vice-chairman and will become an advisor to Giovinazzo.
CellCyte Genetics (Eastgate, WA), an emerging biotechnology company, appointed Douglas Cerretti chief science officer and director of business development. Ceretti will guide the development of CellCyte’s bioreactor product toward commercialization, according to a company press release. The product is a cell expansion device that allows the culture of cells at high density and under precisely controlled oxygenation, providing an alternative to standard cell culture methods.
Cornerstone Therapeutics (Cary, NC), a specialty pharmaceutical company, appointed Andrew K. W. Powell executive vice-president, general counsel, and secretary. Powell will join the company's executive management team and manage its legal function and corporate governance processes. He will report to Craig Collard, the company’s president and CEO.
Eli Lilly (Indianapolis, IN) announced that Steven M. Paul, executive vice-president of science and technology, and president of Lilly Research Laboratories, will retire, effective Feb. 28, 2010. Jan M. Lundberg, executive vice-president and head of global discovery research at AstraZeneca (London), is to become his successor. Lundberg plans to join Lilly in Indianapolis as early as January 2010, subject to completion of the US immigration process, according to a company press release.
Mirna Therapeutics (Austin, TX) appointed Paul Lammers president, CEO, and a member of the board of directors. Lammers is responsible for driving fundamental biological discoveries in the field of microRNA by the Mirna team.
Watson Pharmaceuticals (Morristown, NJ) appointed Robert A. Stewart to newly created position of senior vice-president of global operations. Stewart will have responsibility for global manufacturing, supply chain, quality and technical operations. The company also announced that Thomas R. Russillo, executive vice-president and president of the generics division, was named executive vice-president of global generics and will head the company's newly formed Global Generics business. Both Stewart and Russillo report to Paul Bisaro, president and CEO of Watson.
|
Advertisement:
 Using Lean to Achieve Lab Excellence
3-part complimentary webinar series packed with proven methodologies, best practices, case studies, and actionable advice aimed at helping manufacturers of pharmaceuticals and biologics improve quality and productivity.
Part 1 - Implementing Lean in the Lab
December 2, 2009 2:00PM EST
You'll learn how to:
Assess improvement opportunities
Generate quick wins
Reduce cycle times
Eliminate non-value-added activities
|
|
 |
|
Podcast: Special Supply-Chain Podcast Series |
|
|
|
Listen to the individual audio transcripts from this month’s cover story, featuring Susan J. Schniepp of Javelin Pharmaceuticals, Martin Van Trieste of Rx-360, Janeen Skutnik of IPEC, Tom Buggy of DSM Anti-Infectives, and Susanne Keitel of EDQM.
Coming Soon: Patricia Van Arnum discusses solid-state chemistry with industry experts in the December 2009 issue of Pharmaceutical Technology. |
|
|
|
|
|
|
|
The Next Generation of Innovators
At this month's AAPS Annual Meeting & Exposition, several graduate students were awarded as young innovators. What are your thoughts on innovation and the next generation?
|
View the poll archive. |
|
|
|
Chromatography capsules yield concentrated product
